How Does It Compare to Other Tests?

The Oncotype DX GPS is the only genomic test that was designed specifically for use in men with clinically low risk cancer (GS 3+3 or 3+4) who are deciding between active surveillance or treatment. The test:

Type of Test Result

Genomic Health	Genomic Prostate Score: Predicts the likelihood of Prostate Cancer Death and Metastasis within 10 years after RP, and Adverse Pathology* using multiple genomic pathways
Prolaris® Myriad Genetics	Cell Cycle Progression Score: Reports the risk of dying from untreated disease in ten years, using a single genomic pathway
Decipher® GenomeDx Bioscience	Genomic Classifier: Predicts the probability of metastasis after surgery or radiation using multiple genomic pathways
Promark®† Metamark Genetics	ProMark Score: Predicts likelihood of Adverse Pathology using protein staining
ConfirmMDx® MDx Health	ConfirmMDx result: Predicts likelihood of negative repeat biopsy
4KScore® Opko	4KScore: Provides probability of aggressive cancer on initial biopsy

Validated endpoint(s) in a biopsy setting

Genomic Health	Adverse Pathology Biochemical Recurrence, Prostate Cancer Death and Metastasis within 10 years after RP High Grade Disease Non-Organ Confined Disease
Prolaris® Myriad Genetics	10-year Untreated Mortality Biochemical Recurrence Metastasis after RP
Decipher® GenomeDx Bioscience	High Grade Disease 10-year Metastasis after RP Metastasis after radiation therapy
Promark®† Metamark Genetics	Adverse Pathology High Grade Disease Non-Organ Confined Disease
ConfirmMDx® MDx Health	Negative Repeat Biopsy
4KScore® Opko	Likelihood of GS 3+4 and higher at initial biopsy

Biomarker selection specific for prostate cancer

Genomic Health	YES
Prolaris® Myriad Genetics	NO
Decipher® GenomeDx Bioscience	YES
Promark®† Metamark Genetics	YES
ConfirmMDx® MDx Health	YES
4KScore® Opko	YES

Patient Specimen

Genomic Health	Positive Biopsy NCCN® Very Low, Low, Favorable-Intermediate risk GS 3+3, 3+4
Prolaris® Myriad Genetics	Positive Biopsy AUA® Low-High Risk
Decipher® GenomeDx Bioscience	Positive Biopsy NCCN Low-High Risk
Promark®† Metamark Genetics	Positive Biopsy GS 3+3, 3+4
ConfirmMDx® MDx Health	Negative Biopsy HGPIN Biopsy
4KScore® Opko	Blood Biopsy eligible patients

Patient Access

Genomic Health	Medicare Reimbursed for biopsy NCCN Very Low/Low and Favorable Intermediate Financial Assistance Available
Prolaris® Myriad Genetics	Medicare Reimbursed for biopsy NCCN Very Low/Low and Favorable Intermediate Financial Assistance Available
Decipher® GenomeDx Bioscience	Medicare Reimbursed in Post RP Only Financial Assistance Available
Promark®† Metamark Genetics	Medicare Reimbursed for biopsy NCCN Very Low/Low Financial Assistance Available
ConfirmMDx® MDx Health	Medicare Reimbursed Financial Assistance Available
4KScore® Opko	Financial Assistance is not reported on website

Download Comparison Chart (PDF)

Genomic testing vs. genetic testing

Genetic tests typically screen for inherited risk factors and identify changes in chromosomes and genes—which can help in understanding patient risk for having cancer or other diseases.

Genomic tests examines the expression of genes within a sample of tumor tissue to provide unique information about tumor biology that other clinical pathological factors simply cannot. The activity and interaction of genes influences the aggressiveness of a tumor, including how likely it is to grow and spread.